Lipiodol chemoembolization and additional tamoxifen and verapamil as chemosensitizers in unresectable hepatocellular carcinoma with immunohistochemically P-glycoprotein positive case
Detection of P-glycoprotein positively by immunohistochemistry may affect therapy modalities in patients with hepatocellular carcinoma.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:This report describes the treatment of an advance hepatocellular carcinoma case vvhich has immunohistochemically proven P-glycoprotein positive cells, by chemoembolization and additional tamoxifen and verapamil as chemosensitizers.
📊
Key Findings & Data:Chemotherapy resistance is a major problem in the treatment of patients with hepatocellular carcinoma and P-glycoprotein contributes to the resistance.
💡
Conclusion & Impact:Detection of P-glycoprotein positively by immunohistochemistry may affect therapy modalities in patients with hepatocellular carcinoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Erişkin · İmmünohistokimya · Erkek
Abstract
This report describes the treatment of an advance hepatocellular carcinoma case vvhich has immunohistochemically proven P-glycoprotein positive cells, by chemoembolization and additional tamoxifen and verapamil as chemosensitizers. Chemotherapy resistance is a major problem in the treatment of patients with hepatocellular carcinoma and P-glycoprotein contributes to the resistance. Detection of P-glycoprotein positively by immunohistochemistry may affect therapy modalities in patients with hepatocellular carcinoma.
Özet
Lipiodol chemoembolization and additional tamoxifen and verapamil as chemosensitizers in unresectable hepatocellular carcinoma with immunohistochemically P-glycoprotein positive case
Kane SV, Ganger DR. Management of hepatocellular carcinoma: Staging and treatment. Am J Ther 1997;4:39-45
Kashima Y, Miyazaki M, Ito H, et al. Effective hepatic artery chemoembolization for advanced hepatocellular carcinoma with extensive tumour thrombus through the hepatic vein. J Gastroenterol Hepatol 1999;14:922-7
Llado L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:50-7
Lehne G, De Angelis P, Clausen OP, et al. Human hepatoma cells rich in Pglycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Br J Cancer 1996;74:1719-29
Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-6
Mross K, Hamm D, Hossfeld K. Effects of verapamil on pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 1993;31:369- 75
Rose DM, Chapman WC, Brockenbrough AT, et al. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg 1999;177:405-10
Acunas B, Rozanes I. Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization. Eur J Radiol 1999;32:86-9
Feun LG, Reddy KR, Scagnelli T, et al. A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol 1999;22:375-80
Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-34
Raoul JL. Is chemoembolisation of value in inoperable primary hepatocellular carcinoma. HPB Surg 1998;10:406-8.